6533b81ffe1ef96bd1277ad2
RESEARCH PRODUCT
Daratumumab for the Treatment of Multiple Myeloma
Jakub KrejcikTorben Plesnersubject
Cytotoxicity Immunologic0301 basic medicineOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyAdenosineTreatment outcomeImmunologyDrug Evaluation PreclinicalComplementAntineoplastic AgentsMyelomaimmunomodulationImmunomodulation03 medical and health sciences0302 clinical medicineAntibodies monoclonalimmune system diseasesInternal medicineDaratumumabhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansImmunology and AllergycomplementMultiple myelomaNeonatal Fc-receptorsClinical Trials as Topicbusiness.industryAntibody-Dependent Cell CytotoxicityAntibodies MonoclonalDaratumumabmedicine.diseasedaratumumabTrogocytosis3. Good healthTreatment Outcome030104 developmental biologymyelomaadenosine030220 oncology & carcinogenesisAntibody-dependent cell cytotoxicityMultiple Myelomabusinesslcsh:RC581-607CD38description
This mini-review will summarize the present state of development of the CD38 antibody daratumumab for the treatment of multiple myeloma.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-06-04 | Frontiers in Immunology |